Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
about
Durable cytotoxic immune responses against gp120 elicited by recombinant SV40 vectors encoding HIV-1 gp120 +/- IL-15Low-volume jet injection for intradermal immunization in rabbitsSynthetic DNA vaccine strategies against persistent viral infectionsDNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic miRecombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8+ T-Cell Responses in Rhesus MacaquesMultiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infectionDifferent patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.DNA vaccines against human immunodeficiency virus type 1.Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.Human immunodeficiency virus vaccine trialsInduction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.Allogeneic lymphocytes persist and traffic in feral MHC-matched mauritian cynomolgus macaquesTrogocytosis of MHC-I/peptide complexes derived from tumors and infected cells enhances dendritic cell cross-priming and promotes adaptive T cell responses.Evaluation of a quantitative real-time PCR assay to measure HIV-specific mucosal CD8+ T cell responses in the cervix.Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques.Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression.CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells.Emergence and kinetics of simian immunodeficiency virus-specific CD8(+) T cells in the intestines of macaques during primary infection.Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccinationInduction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virusCellular immune responses to HIV.Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239.Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A*01-positive rhesus macaquesTat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication.Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraGeneration of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection.Challenges in the design of a T cell vaccine in the context of HIV-1 diversity.Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system.DNA/MVA Vaccines for HIV/AIDSThe quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.DNA vaccination.
P2860
Q24792056-9BE932F1-3D0E-4068-90A5-B80AE6469634Q24794453-4B226943-00E3-42F1-B6EB-1972170C044BQ27016078-E235D4D2-273A-44EF-85CD-6B55202F366CQ27473069-949A79F1-25ED-43E1-ACDB-4235D5E74C6AQ27491052-51D94A68-2F82-4BF5-8992-71F5C3F8572FQ28472020-927F4449-5090-416F-A6AA-65B4DC80ADCDQ30330620-B0060446-615B-448A-B7D2-89ADDA99C706Q30342130-B917BC01-60D5-4CF6-8BD0-E19537B0804AQ30359230-8EE8BF4F-41CE-4234-9B42-F50727A9EE4AQ30414377-12C2D210-CBAF-43E6-BE8E-82A535F464EEQ30424366-15E3D1E2-DDE7-45E3-9CF5-F9F220548CF6Q33259057-7D417D68-E2DB-4E0A-B41B-0EECBB617D99Q33342850-06823E14-DC83-4759-A7FD-C5CF1F11F52DQ33366578-9B75C932-1054-44EC-A0BF-4A5E3D3962F8Q33719485-8EE94050-5BFE-4791-BFD7-95CE0263EAB0Q33721009-9EA65B3D-ACEF-42A8-AE52-398F2F15CA98Q33809608-C63E3838-434E-4116-A9D1-0E121336D1C3Q33835440-35F85C6E-4312-4252-B789-F11753FF2FA0Q33844334-D4E084A1-4415-41F8-BEDB-2DFD8A1AA4F1Q33848383-80156DF8-78D2-4C1D-9B09-90F05A538678Q33851802-0585C7A7-000F-4610-AD20-A3DEA7E692C6Q33874561-39820FD6-5AFB-40D9-B91D-3B1A0B5A929DQ34223069-56211A40-86AA-4780-9F9B-94EE8695A2F2Q34226966-2CD25A04-9526-4366-81A4-3DFA787AE94BQ34228494-E00EBAB8-B2CB-4E77-B920-10692BB401E1Q34336210-B5FB337F-3134-4F0F-B1F7-E964E8841958Q34339365-96EBB615-7523-4C31-9449-B9185A4D035BQ34340366-6F14D614-C80D-4333-98AE-5113ABC8BC3DQ34343169-F1CCBEBF-518A-4C62-9BDC-69FBB9EAB55AQ34344205-54BFE53E-89F4-4C91-AD66-899370251FA1Q34348269-01F05631-0CEF-467A-B0F3-7B5ED095272BQ34348640-94A891E3-5A22-4827-8B9E-E4FCC414368DQ34423446-79446E1F-9F6D-4E74-A8A2-58A62A66EAB0Q34471356-1CB94192-99E7-4B3B-9EE0-002AB7D67412Q34492802-7F0FCDE7-791A-417C-82B9-B52E1AE52923Q34632089-265FF8AE-B06F-4593-86ED-101E5EC26A05Q34880294-9BA9B823-0E19-4FAA-8F03-AB8CFAD2A69AQ34940471-371EAA1C-914D-407D-B5D9-BDF64E4D9E9BQ35073970-2A15BCDE-B874-4E35-AEEE-5F4BA66AAE83Q35581126-CB37E4C6-9207-4A5B-AF77-4085E66888C1
P2860
Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@en
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@nl
type
label
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@en
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@nl
prefLabel
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@en
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@nl
P2093
P1476
Induction of AIDS virus-specif ...... ia virus Ankara boost regimen.
@en
P2093
McMichael AJ
P304
P356
10.4049/JIMMUNOL.164.9.4968
P407
P577
2000-05-01T00:00:00Z